Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 709 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Decadron Clear all

Conditions: T-Cell Lymphoma, Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma
Interventions: PEG-L-asparaginase, Dexamethasone acetate; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Dexamethasone, Floxuridine, Implanted Medical Device, Irinotecan, Leucovorin, Oxaliplatin, Quality-of-Life Assessment; Drug · Device · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Lymphoma
Interventions: Cyclophosphamide, Mesna, Vincristine, Methotrexate, Ara-C, Dexamethasone, G-CSF, Doxil; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cataract
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Bronchiolitis, Viral
Interventions: Placebos, Dexamethasone Oral; Drug
Lead sponsor: Allison Williams; Other
Eligibility: 1 Day to 2 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, Burkitt Lymphoma, CD20 Positive, Childhood Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ofatumumab, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Radiation Therapy (RT), Capecitabine, Trastuzumab, Paclitaxel; Radiation · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Plasma Cell Myeloma
Interventions: Belantamab Mafodotin, Dexamethasone, Pomalidomide; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Abatacept, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Buffalo, New York • East Hills, New York • West Islip, New York

Conditions: Macular Edema, Epiretinal Membrane, Vitrectomy
Interventions: Dexamethasone; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Retinal Detachment
Interventions: Dextenza, Prednisolone Acetate; Drug
Lead sponsor: Midwest Eye Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Smoldering Plasma Cell Myeloma
Interventions: Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness, Constipation, Duration of Response, Narcotics Consumption, Pain After Surgery
Interventions: Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks, Ropivacaine with low, non weight based Dexamethasone additive; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Recurrent Plasma Cell Myeloma, T(11;14)
Interventions: Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Venetoclax; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri

Conditions: Lymphoma
Interventions: AMG 531, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hemorrhoids, Fissure in Ano, Rectal Fistula, Anal Condyloma
Interventions: Gabapentin, Ketamine, Acetaminophen, Dexamethasone, Placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Burlington, Vermont • Colchester, Vermont

Conditions: Stiffness Following Total Knee Arthroplasty
Interventions: Dexamethasone, Celecoxib; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Little Rock, Arkansas • Denver, Colorado • Chicago, Illinois + 11 more

Conditions: Obstructive Sleep Apnea
Interventions: Ketorolac, Standard of Care; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 18 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Nausea, Abdominal Pain
Interventions: Ondansetron, Dexamethasone; Drug
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acanthamoeba Keratitis
Interventions: Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo; Drug · Other
Lead sponsor: Jeremy Keenan, MD, MPH; Other
Eligibility: 8 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma
Interventions: Biospecimen Collection, Computed Tomography, Dexamethasone, Invasive Procedure, Magnetic Resonance Imaging, RAGE Antagonist FPS-ZM1, Resection; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: Dexamethasone, Vincristine, Inotuzumab, Blinatumomab, Dasatinib, IT MHA, Cyclophosphamide, Cytarabine, Methotrexate, 6-Mercaptopurine, Calaspargase, Daunorubicin, Thioguanine; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 3
States / cities: Charlotte, North Carolina • Tulsa, Oklahoma • Memphis, Tennessee

Conditions: Leukemia
Interventions: cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, vincristine sulfate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

Steroid Use in Non-RSV Bronchiolitis

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane

Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Pre-Emptive Analgesia in Ano-Rectal Surgery

MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty

Effect of Ketorolac on Post Adenotonsillectomy Pain

Ondansetron Versus Dexamethasone/Ondansetron to Treat Acute Nausea in the Emergency Department

Parasitic Ulcer Treatment Trial

FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia